Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Age
18–79
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Signed Informed Consent
Have a BMI ≥27.0 kg/m2 at Screening
Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening
You may not be if
Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
Self-reported change in body weight \>5 kg (11 pounds) within 3 months before Screening.
Have prior or planned surgical or non-surgical treatment for obesity.
Clareo Health | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
